Effect of inclisiran on atherogenic lipoproteins in high-risk primary prevention populations: analysis from the phase III ORION-11 trial

K.K. Ray,D. Kallend,L.A. Leiter,F.J. Raal,W. Koenig, M.J. Jaros,G.G. Schwartz,U. Landmesser,P.L. Wijngaard,R.S. Wright,J.J. Kastelein

Atherosclerosis（2020）

引用 0|浏览1

暂无评分

摘要

Background and Aims: ESC/EAS guidelines recommend statins as first-line treatment for primary prevention of ASCVD but many of these patients require additional therapies to achieve LDL-C targets. We assessed the effect of inclisiran on atherogenic lipids in the primary prevention cohort of the ORION-11 trial.

查看译文

关键词

atherogenic lipoproteins,inclisiran,primary prevention populations,high-risk

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要